Endonovo Therapeutics, Inc.
ENDV
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1,688.11% | 2,289.19% | 442.26% | 85.36% | -83.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,688.11% | 2,289.19% | 442.26% | 85.36% | -83.04% |
| Cost of Revenue | -30.71% | -1.53% | 0.76% | -33.33% | -73.63% |
| Gross Profit | 81,900.00% | 13,373.68% | 651.09% | 115.46% | -99.04% |
| SG&A Expenses | -9.28% | -13.61% | 63.55% | 48.37% | 64.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.37% | -13.57% | 63.17% | 47.83% | 20.92% |
| Operating Income | 17.07% | 21.19% | -55.89% | -46.61% | -24.37% |
| Income Before Tax | -39.97% | -4.29% | -211.25% | -495.00% | 58.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.97% | -4.29% | -211.25% | -495.00% | 58.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.97% | -4.29% | -211.25% | -495.00% | 58.22% |
| EBIT | 17.07% | 21.19% | -55.89% | -46.61% | -24.37% |
| EBITDA | 21.47% | 26.26% | -80.42% | -65.87% | -32.91% |
| EPS Basic | -67.96% | 9.57% | -44.32% | -57.59% | 90.25% |
| Normalized Basic EPS | -55.63% | 0.41% | -49.82% | -59.71% | 89.28% |
| EPS Diluted | -230.28% | -79.22% | -114.62% | -59.14% | 89.68% |
| Normalized Diluted EPS | -187.32% | -76.23% | -105.49% | -59.71% | 89.28% |
| Average Basic Shares Outstanding | 130.54% | 146.53% | 162.80% | 131.95% | 136.33% |
| Average Diluted Shares Outstanding | 713.22% | 873.30% | 700.91% | 131.95% | 136.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
